Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Work
Year: 2017
Type: article
Source: The Lancet
Institutions USC Norris Comprehensive Cancer Center, Clinica Universidad de Navarra, Centro de Investigación Biomédica en Red, University of Hong Kong, Providence Portland Medical Center +16 more
Cites: 31
Cited by: 3,816
Related to: 10
FWCI: 239.2
Citation percentile (by year/subfield): 99.98
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal No poverty
Open Access status: green